Nektar Therapeutics (NKTR) closed its public offering of almost 7.64 million shares, raising $460 million.
The offering included 1.03 million shares sold to underwriters exercising their option to purchase additional stock, as well as 293,103 prefunded warrants, the company said Friday in a statement.
The stock was sold at $58 a share.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.